Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Jun 2019 to Jun 2024
Aclara to Present at Needham Third Annual Biotechnology
Conference
MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- ACLARA BioSciences
(NASDAQ:ACLA) announced today that Thomas G. Klopack, ACLARA's chief executive
officer will present at the Needham Third Annual Biotechnology Conference on
Thursday, June 17, 2004 at 8:30 a.m. EDT at the Palace Hotel in New York.
About ACLARA
Founded in 1995, ACLARA is a biotechnology company working to provide
physicians and researchers products and services to make personalized medicine
a reality through its protein-based assay technology -- the eTag(TM) System.
ACLARA is dedicated to unlocking the power of pathway biology to accelerate the
development of next-generation targeted therapeutics, recognizing the most
appropriate patients for approved therapies and identifying the
highly-specific, protein-based biomarkers that will enable physicians to create
truly personalized treatment regimens for patients suffering from cancer and
other life-threatening disorders.
ACLARA is commercializing its proprietary eTag System to enhance and accelerate
drug discovery research and the preclinical and clinical development of
targeted therapeutics. ACLARA's technology may also enable the development of
highly-specific, protein-based diagnostics capable of providing physicians with
a powerful tool for creating personalized treatment regimens for patients
suffering from serious and difficult-to-treat cancers. For more information on
ACLARA please visit the Company's web site at http://www.aclara.com/.
Forward-Looking Statements
All statements in this news release that are not historical are forward-looking
statements within the meaning of the Securities Exchange Act of 1934 as
amended. Such forward-looking statements are subject to factors that could
cause actual results to differ materially for ACLARA from those projected.
Those factors include risks and uncertainties relating to the performance of
our products, anticipated progress in commercialization of our eTag(TM) assay
system; the potential for use of our eTag assays in clinical development
programs; the potential for use of our eTag assays as diagnostic tests; our
ability to successfully conduct clinical studies and the results obtained from
those studies; our ability to establish reliable, high-volume operations at
commercially reasonable costs; expected reliance on a few customers for the
majority of our revenues; actual market acceptance of our products and adoption
of our technological approach and products by pharmaceutical and biotechnology
companies; our estimate of the size of our markets; our estimates of the levels
of demand for our products; our ability to develop organizational capabilities
suitable for the further development and commercialization of our eTag assays;
the ultimate validity and enforceability of our patent applications and
patents; the possible infringement of the intellectual property of others;
technological approaches of ACLARA and our competitors; our pending merger with
ViroLogic, Inc., including the risk that the closing conditions or the merger
may not be satisfied and the merger may not be completed, and costs related to
the proposed merger; and other risk factors identified in our Form 10-Q for the
quarter ended March 31, 2004 as filed with the Securities and Exchange
Commission.
NOTE: ACLARA BioSciences is a registered trademark, and eTag and the ACLARA
logo are trademarks of ACLARA BioSciences, Inc.
DATASOURCE: ACLARA BioSciences
CONTACT: Alfred Merriweather, VP, Finance and CFO of ACLARA BioSciences,
+1-650-210-1200, or
Web site: http://www.aclara.com/